Document and Entity Information
Document and Entity Information | Dec. 21, 2021 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001664106 |
Document Type | 8-K/A |
Document Period End Date | Dec. 21, 2021 |
Entity Registrant Name | LOGICBIO THERAPEUTICS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38707 |
Entity Tax Identification Number | 47-1514975 |
Entity Address, Address Line One | 65 Hayden Avenue |
Entity Address, Address Line Two | 2nd Floor |
Entity Address, City or Town | Lexington |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02421 |
City Area Code | (617) |
Local Phone Number | 245-0399 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.0001 per share |
Trading Symbol | LOGC |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
Amendment Description | On December 22, 2021, LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing that, on and effective December 21, 2021, the Board of Directors of the Company (the “Board”) increased the Board’s size from eight to nine directors and appointed Susan R. Kahn to serve as a Class II director. Committee assignments for Ms. Kahn were not determined as of the filing of the Original Form 8-K. This Current Report on Form 8-K/A hereby amends Item 5.02 of the Original Form 8-K to disclose that, on and effective March 17, 2022, the Board appointed Ms. Kahn to serve on the Nominating and Corporate Governance Committee of the Board. |